In Austria, multiple individuals were hospitalized after consuming counterfeit Ozempic medication.

In Austria, multiple individuals were hospitalized after consuming counterfeit Ozempic medication.
Spread the love

A number of Austrians received medical treatment in the hospital after using a suspected counterfeit weight-loss drug, Ozempic

 

Austria’s Federal Office for Safety in Health Care (BASG) reported “serious side effects,” including low blood sugar and seizures, among those who had used the weight-loss drug Ozempic. The BASG indicated that the drugs falsely contained insulin instead of Ozempic’s active ingredient, semaglutide. Ozempic has gained popularity as a weight-loss treatment. An investigation is currently ongoing.

The Austrian Criminal Intelligence Service (BK) revealed that the affected individuals had received the syringes from an Austrian-based doctor. They cautioned that counterfeit stocks of the drug might still be in circulation.

The counterfeit injection pens were distinguished by a darker blue color compared to the authentic ones, as noted by Austria’s Federal Office for Safety in Health Care. The agency has advised doctors and patients to inspect their supplies.

 

The statement from the agency mentioned that Ozempic has been increasingly employed for weight loss purposes, even though it’s not approved for such use. Both the Austrian police and the Ministry of Health have cautioned the public against using weight-loss injections from untrustworthy sources.

The European Medicines Agency (EMA) had previously cautioned that the rising demand for Ozempic had resulted in a shortage for diabetic patients. Recently, the EMA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a warning that counterfeit Ozempic injection pens from suppliers in Austria and Germany were found in UK and EU wholesalers.

 

The MHRA assured that all affected pens have been recalled and tracked, and none of these pens had been distributed to patients in the UK.

The MHRA stated that it is collaborating closely with its regulatory counterparts worldwide to ensure the continued security of the broader supply chain, both domestically and internationally.

 

For Similar news: https://initiatemagazine.com/

Contact for Ads and Announcements:  +92 3152042287

Email: Contact@initiatemagazine.com


Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *